Serina Therapeutics, Inc. SER · Stock Open Serina Therapeutics, Inc. in new tab
Serina Therapeutics, Inc. Analysis (SER)
Is Serina Therapeutics, Inc. a good investment? Serina Therapeutics, Inc. (SER) is currently trading at 1.90 USD.
Earnings Schedule: Serina Therapeutics, Inc. is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is -1.05.
Investor FAQ
Does Serina Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Serina Therapeutics, Inc.?
Serina Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of -2.00.
Company Profile
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
| Split Date | Split Ratio to 1 |
|---|---|
| March 15, 2024 | 0.028000 |
| March 15, 2024 | 0.030000 |
Community Discussion